Confronting convention
We take risks and challenge the status quo because disease must be fought with unexpected practice.
Unlike traditional therapeutic approaches that target growth factors in their active states, Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors with the aim of avoiding toxicity and improving efficacy.
Learn About Our ScienceScholar Rock works across therapeutic areas and shines new light on the overlooked to better target disease.
Our growing team is replete with good people who eat, sleep, and breathe good science. We promote a spirit of inquiry outside one’s traditional expertise to uncover enlightened solutions for patients.
Exploration
Our Growing Pipeline
Follow our product candidates on their journeys to fighting serious diseases.
Spinal Muscular Atrophy
Apitegromab
(SRK-015)
Inhibit the activation of latent myostatin to promote a potentially clinically-beneficial increase in muscle function
Oncology
SRK-181
Potential to overcome primary resistance to checkpoint inhibitors to reach a larger patient population
Fibrosis
In partnership with Gilead Sciences
Inhibit TGFβ signaling to potentially offer a powerful new approach to suppressing pro-fibrotic signaling in multiple organs
Iron-Restricted Anemias
Target RGMc—a co-receptor of BMP6—to potentially treat diseases associated with dysregulation of iron metabolism
October 3, 2021
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
September 30, 2021
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
September 28, 2021
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
Events
View More EventsLet’s Connect
Let’s talk science, let’s talk you! We’d love to hear from you and answer any questions you may have.
Join Our Team
We’re a group of thinkers and doers who fight disease from a new angle.